South Dakota Investment Council Has $1.82 Million Position in Shockwave Medical, Inc. (NASDAQ:SWAV)

South Dakota Investment Council boosted its position in Shockwave Medical, Inc. (NASDAQ:SWAV) by 55.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,524 shares of the company’s stock after purchasing an additional 3,410 shares during the period. South Dakota Investment Council’s holdings in Shockwave Medical were worth $1,815,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. New York State Common Retirement Fund increased its stake in shares of Shockwave Medical by 0.9% in the fourth quarter. New York State Common Retirement Fund now owns 209,395 shares of the company’s stock valued at $39,902,000 after buying an additional 1,945 shares during the period. Jennison Associates LLC increased its stake in shares of Shockwave Medical by 13.1% in the fourth quarter. Jennison Associates LLC now owns 100,551 shares of the company’s stock valued at $19,161,000 after buying an additional 11,651 shares during the period. Cetera Trust Company N.A acquired a new stake in shares of Shockwave Medical in the fourth quarter valued at about $152,000. Handelsbanken Fonder AB increased its stake in shares of Shockwave Medical by 10.9% in the fourth quarter. Handelsbanken Fonder AB now owns 7,100 shares of the company’s stock valued at $1,353,000 after buying an additional 700 shares during the period. Finally, Robbins Farley increased its stake in shares of Shockwave Medical by 1.0% in the fourth quarter. Robbins Farley now owns 4,542 shares of the company’s stock valued at $866,000 after buying an additional 45 shares during the period. Institutional investors and hedge funds own 95.35% of the company’s stock.

Insiders Place Their Bets

In other Shockwave Medical news, CFO Dan Puckett sold 3,406 shares of Shockwave Medical stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $229.76, for a total transaction of $782,562.56. Following the completion of the sale, the chief financial officer now owns 27,732 shares of the company’s stock, valued at approximately $6,371,704.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Dan Puckett sold 3,406 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $229.76, for a total value of $782,562.56. Following the completion of the transaction, the chief financial officer now owns 27,732 shares of the company’s stock, valued at approximately $6,371,704.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Laura Francis sold 1,500 shares of Shockwave Medical stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $300.00, for a total value of $450,000.00. Following the completion of the transaction, the director now owns 3,551 shares of the company’s stock, valued at approximately $1,065,300. The disclosure for this sale can be found here. In the last 90 days, insiders sold 93,813 shares of company stock valued at $23,762,679. 3.40% of the stock is owned by company insiders.

Shockwave Medical Trading Up 0.1 %

SWAV opened at $328.87 on Thursday. The stock’s fifty day moving average is $291.68 and its two-hundred day moving average is $231.69. The company has a market capitalization of $12.30 billion, a P/E ratio of 84.98, a PEG ratio of 2.44 and a beta of 0.92. Shockwave Medical, Inc. has a 52 week low of $157.00 and a 52 week high of $331.58. The company has a quick ratio of 10.73, a current ratio of 11.76 and a debt-to-equity ratio of 1.09.

Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings data on Thursday, February 15th. The company reported $1.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.24. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. The firm had revenue of $202.98 million during the quarter, compared to analysts’ expectations of $199.43 million. During the same quarter last year, the firm earned $3.71 EPS. The business’s quarterly revenue was up 41.0% on a year-over-year basis. Analysts forecast that Shockwave Medical, Inc. will post 4.94 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on SWAV shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $335.00 target price (up previously from $285.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Wolfe Research reiterated a “peer perform” rating on shares of Shockwave Medical in a report on Friday, April 5th. Wells Fargo & Company increased their price target on Shockwave Medical from $200.00 to $210.00 and gave the stock an “equal weight” rating in a report on Friday, February 16th. Canaccord Genuity Group reiterated a “hold” rating and issued a $335.00 price target (up previously from $263.00) on shares of Shockwave Medical in a report on Friday, April 5th. Finally, Needham & Company LLC restated a “hold” rating on shares of Shockwave Medical in a report on Friday, April 5th. Ten analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Shockwave Medical presently has an average rating of “Hold” and a consensus target price of $309.11.

About Shockwave Medical

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.